{"id":"https://openalex.org/W7093123799","doi":null,"title":"SP21 | SAFE AND EFFECTIVE USE OF MOSUNETUZUMAB IN A VERY ELDERLY PATIENT WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: A CASE REPORT","display_name":"SP21 | SAFE AND EFFECTIVE USE OF MOSUNETUZUMAB IN A VERY ELDERLY PATIENT WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: A CASE REPORT","publication_year":2025,"publication_date":"2025-09-01","ids":{"openalex":"https://openalex.org/W7093123799"},"language":"en","primary_location":{"id":"pmh:oai:doaj.org/article:e6b9816d115441bbadd8329137270fe5","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/e6b9816d115441bbadd8329137270fe5","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Haematologica, Vol 110, Iss s1 (2025)","raw_type":"article"},"volume":null,"type":"article","indexed_in":["doaj"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://doaj.org/article/e6b9816d115441bbadd8329137270fe5","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5067472155","display_name":"Felicina Li Gioi","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"F. Li Gioi","raw_affiliation_strings":["UOC Ematologia, AO Papardo"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UOC Ematologia, AO Papardo","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"C. Campo","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. Campo","raw_affiliation_strings":["UOC Ematologia, AO Papardo"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UOC Ematologia, AO Papardo","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051243958","display_name":"Gabriella Cancemi","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"G. Cancemi","raw_affiliation_strings":["UOC Ematologia, AO Papardo"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UOC Ematologia, AO Papardo","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007333218","display_name":"Laura Nocilli","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"L. Nocilli","raw_affiliation_strings":["UOC Ematologia, AO Papardo"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UOC Ematologia, AO Papardo","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064125825","display_name":"Santo Neri","orcid":"https://orcid.org/0000-0003-2429-4886","observed_orcids":["https://orcid.org/0000-0003-2429-4886"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. Neri","raw_affiliation_strings":["UOC Ematologia, AO Papardo"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UOC Ematologia, AO Papardo","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016140739","display_name":"Valeria Di Giacomo","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"V. Di Giacomo","raw_affiliation_strings":["UOC Ematologia, AO Papardo"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UOC Ematologia, AO Papardo","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5022006811","display_name":"Donato Mannina","orcid":"https://orcid.org/0000-0001-8665-1258","observed_orcids":["https://orcid.org/0000-0001-8665-1258"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. Mannina.","raw_affiliation_strings":["UOC Ematologia, AO Papardo"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UOC Ematologia, AO Papardo","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.48427118,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":true,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9926999807357788,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9926999807357788,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.00419999985024333,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.0007999999797903001,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/mosunetuzumab","display_name":"mosunetuzumab","score":1.0},{"id":"https://openalex.org/keywords/relapsed-refractory-follicular-lymphoma","display_name":"relapsed/refractory follicular lymphoma","score":0.9139999747276306},{"id":"https://openalex.org/keywords/very-elderly-patients","display_name":"very elderly patients","score":0.843999981880188},{"id":"https://openalex.org/keywords/cd20xcd3-bispecific-antibody","display_name":"CD20xCD3 bispecific antibody","score":0.9470000267028809},{"id":"https://openalex.org/keywords/cytokine-release-syndrome","display_name":"cytokine release syndrome","score":0.9350000023841858},{"id":"https://openalex.org/keywords/chronic-kidney-disease","display_name":"chronic kidney disease","score":0.7369999885559082},{"id":"https://openalex.org/keywords/comorbidity","display_name":"comorbidities","score":0.718999981880188},{"id":"https://openalex.org/keywords/treatment-safety-and-feasibility","display_name":"treatment safety and feasibility","score":0.6119999885559082},{"id":"https://openalex.org/keywords/tocilizumab","display_name":"tocilizumab","score":0.8870000243186951},{"id":"https://openalex.org/keywords/deauville-score","display_name":"Deauville score","score":0.7459999918937683}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9531000256538391},{"id":"https://openalex.org/C2777058707","wikidata":"https://www.wikidata.org/wiki/Q123251","display_name":"Follicular lymphoma","level":3,"score":0.6807000041007996},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.6482999920845032},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.4661000072956085},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.46059998869895935},{"id":"https://openalex.org/C2779951463","wikidata":"https://www.wikidata.org/wiki/Q7268788","display_name":"Quality of life (healthcare)","level":2,"score":0.3587000072002411},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.35659998655319214},{"id":"https://openalex.org/C2775934546","wikidata":"https://www.wikidata.org/wiki/Q179991","display_name":"Biopsy","level":2,"score":0.35499998927116394},{"id":"https://openalex.org/C187785154","wikidata":"https://www.wikidata.org/wiki/Q5464664","display_name":"Follicular phase","level":2,"score":0.34619998931884766},{"id":"https://openalex.org/C509974204","wikidata":"https://www.wikidata.org/wiki/Q180507","display_name":"Radiation therapy","level":2,"score":0.33070001006126404},{"id":"https://openalex.org/C2779384505","wikidata":"https://www.wikidata.org/wiki/Q17007513","display_name":"Concomitant","level":2,"score":0.3285999894142151},{"id":"https://openalex.org/C2780849966","wikidata":"https://www.wikidata.org/wiki/Q170758","display_name":"Lymph node","level":2,"score":0.3239000141620636},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.3183000087738037},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.30880001187324524},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3068000078201294},{"id":"https://openalex.org/C2779719350","wikidata":"https://www.wikidata.org/wiki/Q412920","display_name":"Daclizumab","level":4,"score":0.30149999260902405},{"id":"https://openalex.org/C2778818763","wikidata":"https://www.wikidata.org/wiki/Q6708226","display_name":"Lymph node biopsy","level":3,"score":0.2915000021457672},{"id":"https://openalex.org/C146357865","wikidata":"https://www.wikidata.org/wiki/Q1123245","display_name":"Stage (stratigraphy)","level":2,"score":0.2896000146865845},{"id":"https://openalex.org/C2779714933","wikidata":"https://www.wikidata.org/wiki/Q289306","display_name":"B symptoms","level":3,"score":0.2867000102996826},{"id":"https://openalex.org/C526584372","wikidata":"https://www.wikidata.org/wiki/Q16399","display_name":"Thyroid","level":2,"score":0.2827000021934509},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.2806999981403351},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.27469998598098755},{"id":"https://openalex.org/C2781392513","wikidata":"https://www.wikidata.org/wiki/Q916398","display_name":"Lymphedema","level":4,"score":0.27059999108314514},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.2653000056743622},{"id":"https://openalex.org/C2779015954","wikidata":"https://www.wikidata.org/wiki/Q420164","display_name":"Alemtuzumab","level":3,"score":0.26420000195503235},{"id":"https://openalex.org/C2777178219","wikidata":"https://www.wikidata.org/wiki/Q425154","display_name":"Tocilizumab","level":3,"score":0.2547999918460846},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.25290000438690186}],"mesh":[],"locations_count":1,"locations":[{"id":"pmh:oai:doaj.org/article:e6b9816d115441bbadd8329137270fe5","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/e6b9816d115441bbadd8329137270fe5","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Haematologica, Vol 110, Iss s1 (2025)","raw_type":"article"}],"best_oa_location":{"id":"pmh:oai:doaj.org/article:e6b9816d115441bbadd8329137270fe5","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/e6b9816d115441bbadd8329137270fe5","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Haematologica, Vol 110, Iss s1 (2025)","raw_type":"article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"sustainable_development_goals_aurora":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":[],"abstract_inverted_index":{"Background:":[0],"Mosunetuzumab,":[1],"a":[2,10,116,222],"CD20xCD3":[3],"bispecific":[4,276],"antibody,":[5],"has":[6],"shown":[7],"efficacy":[8],"and":[9,74,92,109,146,157,195,231,243,263,267],"favorable":[11],"safety":[12,244],"profile":[13],"in":[14,36,46,66,80,112,247,279],"relapsed/refractory":[15],"follicular":[16,132],"lymphoma":[17],"(FL).":[18],"Clinical":[19],"trials":[20],"report":[21],"durable":[22],"responses":[23],"with":[24,40,68,78,88,102,193,199],"manageable":[25],"toxicity,":[26],"mostly":[27],"low-grade":[28],"cytokine":[29],"release":[30],"syndrome":[31,208],"(CRS).":[32],"However,":[33],"real-world":[34,285],"data":[35,292],"patients":[37,274],">85":[38],"years":[39],"comorbidities":[41],"are":[42],"lacking.":[43],"Documenting":[44],"feasibility":[45,242],"such":[47],"cases":[48],"is":[49],"critical":[50],"to":[51,54,287],"expanding":[52],"access":[53],"novel":[55],"immunotherapies.":[56],"Case":[57],"Report:":[58],"A":[59,182],"female":[60],"patient":[61,228,254],"aged":[62],">89":[63],"was":[64,164,179],"diagnosed":[65],"2018":[67],"grade":[69,130,184],"II,":[70],"stage":[71],"IV":[72],"FL":[73],"achieved":[75],"complete":[76],"remission":[77],"R-CHOP,":[79],"other":[81],"center.":[82],"In":[83],"2024,":[84],"clinical":[85,297],"relapse":[86],"presented":[87],"left":[89,94,123],"leg":[90],"lymphedema":[91],"palpable":[93],"inguinal":[95,124],"lymphadenopathy.":[96],"PET-CT":[97],"showed":[98,221],"subdiaphragmatic":[99],"nodal":[100],"involvement":[101],"high":[103],"metabolic":[104],"activity":[105],"(SUV":[106],"max":[107],"7.99)":[108],"moderate":[110,268],"uptake":[111],"supradiaphragmatic":[113],"regions,":[114],"including":[115,148],"small":[117],"mediastinal":[118],"node.":[119],"Biopsy":[120],"of":[121,129,225,233,245,291,294],"the":[122,190,241,288],"lymph":[125],"node":[126],"confirmed":[127],"recurrence":[128],"II":[131],"lymphoma.":[133],"Rituximab":[134],"monotherapy":[135],"(4":[136],"doses)":[137],"proved":[138],"ineffective,":[139],"confirming":[140],"refractory":[141],"disease.":[142],"Despite":[143],"advanced":[144],"age":[145],"comorbidities,":[147,262],"chronic":[149],"kidney":[150],"disease":[151],"(ClCr":[152],"32":[153],"mL/min),":[154],"ECOG":[155,259],"1":[156],"functional":[158],"independence":[159],"were":[160,171,214],"preserved.":[161],"Mosunetuzumab":[162],"therapy":[163,278],"started":[165],"after":[166,189,218],"multidisciplinary":[167],"evaluation.":[168],"Five":[169],"cycles":[170],"completed":[172],"without":[173],"dose":[174],"delays,":[175],"or":[176,212],"modifications.":[177],"Treatment":[178],"well":[180],"tolerated.":[181],"single":[183],"2":[185],"CRS":[186],"episode":[187],"occurred":[188],"first":[191],"dose,":[192],"fever":[194],"desaturation,":[196],"resolved":[197],"promptly":[198],"tocilizumab":[200],"(8":[201],"mg/kg).":[202],"No":[203],"immune":[204],"effector":[205],"cell-associated":[206],"neurotoxicity":[207],"(ICANS),":[209],"severe":[210],"cytopenias,":[211],"infections":[213],"observed.":[215],"Interim":[216],"PET":[217],"cycle":[219],"5":[220],"Deauville":[223],"Score":[224],"2.":[226],"The":[227],"maintained":[229],"autonomy":[230],"quality":[232],"life":[234],"throughout":[235],"treatment.":[236],"Conclusion:":[237],"This":[238,282],"case":[239],"supports":[240],"mosunetuzumab":[246],"very":[248],"elderly":[249],"patients.":[250],"Key":[251],"parameters":[252],"for":[253],"selection":[255],"must":[256],"include":[257],"preserved":[258],"status,":[260],"controlled":[261,296],"close":[264],"monitoring.":[265],"Age":[266],"renal":[269],"dysfunction":[270],"should":[271],"not":[272],"exclude":[273],"from":[275],"antibody":[277],"appropriate":[280],"settings.":[281,299],"experience":[283],"adds":[284],"evidence":[286],"growing":[289],"body":[290],"outside":[293],"strictly":[295],"trial":[298]},"counts_by_year":[],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2025-10-22T00:00:00"}